Blueprint

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ______________ to _____________

Commission file number: 333-140645

TONGJI HEALTHCARE GROUP, INC.

(Exact name of registrant as specified in its charter)

Nevada		99-0364697
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

No. 5 Beiji Road Nanning, Guangxi, People’s Republic of China		530011
(Address of principal executive offices)		(Zip Code)

011-86-771-2020000

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:

As of May 19, 2017, there were 15,812,191 shares of $0.001 par value common stock issued and outstanding.

FORM 10-Q

TONGJI HEALTHCARE GROUP, INC.

INDEX

		Page

PART I.	Financial Information	4

	Item 1. Financial Statements (Unaudited).	4

	Condensed Consolidated Balance Sheets as of March 31, 2017 (Unaudited) and December 31, 2016.	4

	Condensed Consolidated Statements of Operations and Comprehensive Income (loss) for the Three Months Ended March 31, 2017 and 2016 (Unaudited).	5

	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2017 and 2016 (Unaudited).	6

	Notes to Condensed Consolidated Financial Statements as of March 31, 2017 (Unaudited).	7

	Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	18

	Item 3. Quantitative and Qualitative Disclosures About Market Risk.	22

	Item 4. Controls and Procedures.	22

PART II.	Other Information	24

	Item 1. Legal Proceedings.	24

	Item 1A. Risk Factors.	24

	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.	24

	Item 3. Defaults Upon Senior Securities.	24

	Item 4. Mine Safety Disclosures.	24

	Item 5. Other Information.	24

	Item 6. Exhibits.	25

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

The unaudited condensed consolidated financial statements of registrant as of March 31, 2017 and December 31, 2016 and for the three months ended March 31, 2017 and 2016 follow. The condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal and recurring nature.

TONGJI HEALTHCARE GROUP, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS


	March 31, 2017	December 31, 2016
	(Unaudited)	(Audited)
ASSETS

Current Assets
Cash	$42,251	$47,597
Accounts receivable, net	190,599	239,377
Due from related parties	186,975	185,365
Other current receivable	7,305,954	7,243,028
Medical supplies	16,289	52,357
Prepaid expenses and other current assets	13,201	13,087

Total Current Assets	7,755,269	7,780,811

Equipment, net	371,504	386,158


Deposit	172,966	171,476

Intangible assets, net	23,269	25,301

TOTAL ASSETS	$8,323,008	$8,363,746

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current Liabilities
Accounts payable and accrued expenses	$957,616	$997,040
Due to related parties	10,499,289	10,371,235
Other payable	1,318,709	1,269,176
Settlement payable	1,399,980	1,366,639
Short-term loan	-	-
Current portion of capital lease payable	526,922	522,384

Total Current Liabilities	14,702,516	14,526,474

Total Liabilities	14,702,516	14,526,474

STOCKHOLDERS' DEFICIT
Preferred stock; $0.001 par value, 20,000,000 shares authorized and none issued and outstanding	-	-
Common stock; $0.001 par value, 50,000,000 shares authorized and 15,812,191 shares issued and outstanding as of March 31, 2017 and December 31, 2016 respectively	15,812	15,812
Additional paid in capital	440,368	440,368
Accumulated deficit	(7,369,605)	(7,206,416)
Accumulated other comprehensive income	533,917	587,508

Total Stockholders' Deficit	(6,379,508)	(6,162,728)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$8,323,008	$8,363,746


The accompanying notes are an integral part of these consolidated financial statements.

TONGJI HEALTHCARE GROUP, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE THREE MONTH PERIODS ENDED MARCH 31
(UNAUDITED)

	March 31, 2017	March 31, 2016

OPERATING REVENUE
In-patient service revenue	$194,626	$257,902
Out-patient service revenue	143,770	243,764
Total operating revenue	338,396	501,666

OPERATING EXPENSES
Administrative expenses	65,229	45,916
Depreciation and amortization expenses	20,254	17,977
Medicine and supplies	144,050	241,302
Other operating expenses	49,749	73,253
Salary and fringes	139,894	175,159
Total operating expenses	419,176	553,607

LOSS FROM OPERATIONS	(80,780)	(51,941)

OTHER INCOME (EXPENSE)
Other income	6,449	7,451
Interest expense, net	(88,858)	(80,815)
Total Other Expense	(82,409)	(73,364)

LOSS BEFORE INCOME TAXES	(163,189)	(125,305)

Provision for income taxes	-	-

NET LOSS	(163,189)	(125,305)

OTHER COMPREHENSIVE INCOME(LOSS)
Foreign currency translation gain (loss)	(53,591)	(15,061)

NET COMPREHENSIVE INCOME (LOSS)	$(216,780)	$(140,366)

Net loss per common stock-Basic and Diluted	$(0.014)	$(0.009)


Weighted average common stock outstanding
Basic and Diluted	15,812,191	15,812,191

The accompanying notes are an integral part of these consolidated financial statements.

TONJI HEALTHCARE GROUP, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTH ENDED MARCH 31
(UNAUDITED)

	2017	2016
Operating activities:
Net loss	$(163,189)	$(125,305)
Adjustments to reconcile net loss to
Net cash provided by (used in) operating activities:
Depreciation expense	20,254	17,977
Increase/(decrease) in operating assets and liabilities:
Accounts receivable	50,842	40,600
Medical supplies	36,511	80,301
Prepaid expense and other current assets	(2)	(1,921)
Other receivable	2	(2,384)
Accounts payable and accrued expenses	(48,072)	(41,955)
Other payables	38,495	28,243
Contingent liability	21,461	23,104

Net Cash Use in Operating Activities	(43,698)	18,660

Investing activities:
Acquisitions of fixed assets	-	(6,641)
Construction in progress	-	(44,316)

Net Cash Used in Investing Activities	-	(50,957)

Financing activities:
Due to related parties	37,940	64,339

Net Cash Provided by Financing Activities	37,940	64,339

Effect of Exchange Rate Changes in Cash and Cash Equivalent	412	499

Net increase (decrease) in Cash	(5,346)	32,541

Cash-Beginning of Period	47,597	10,300

Cash-Ending of Period	$42,251	$42,841

Cash Paid During the Year for:
Income taxes	$-	$-
Interest paid	$6,570	$4,756

The accompanying notes are an integral part of these consolidated financial statements.

TONGJI HEALTHCARE GROUP, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(UNAUDITED)

NOTE 1- ORGANIZATION

Nanning Tongji Hospital, Inc. ("NTH") was established in Nanning in the province of Guangxi of the People’s Republic of China ("PRC" or “China”) by the Nanning Tongji Medical Co. Ltd. and an individual on October 30, 2003.

NTH is a designated hospital for medical insurance in the city of Nanning and Guangxi province. NTH specializes in the areas of internal medicine, surgery, gynecology, pediatrics, emergency medicine, ophthalmology, medical cosmetology, rehabilitation, dermatology, otolaryngology, traditional Chinese medicine, medical imaging, anesthesia, acupuncture, physical therapy, health examination, and prevention.

On December 19, 2006, NTH filed the Articles of Incorporation in the State of Nevada to establish Tongji Healthcare Group, Inc. (the "Company"). On the same day, Tongji, Inc., a wholly owned subsidiary of the Company, was incorporated in the State of Colorado. Tongji Inc. was later dissolved on March 25, 2011.

On December 27, 2006, Tongji Inc. acquired 100% of the equity in NTH pursuant to an Agreement and Plan of Merger, pursuant to which NTH became a wholly owned subsidiary of Tongji Inc. Pursuant to the Agreement and Plan of Merger, the Company issued 15,652,557 shares of common stock to the stockholders of NTH in exchange for 100% of the issued and outstanding shares of common stock of NTH. Thereafter and for purposes of these consolidated financial statements the "Company" and "NTH" are used to refer to the operations of NTH. The acquisition of NTH was accounted for as a reverse acquisition under the purchase method of accounting since the stockholders of NTH obtained control of the consolidated entity. Accordingly, the reorganization of the two companies was recorded as a recapitalization of NTH, with NTH being treated as the continuing operating entity.

The Company is authorized to issue 50,000,000 shares of common stock, par value $0.001 per share and 20,000,000 shares of preferred stock, par value $0.001 per share.

According to the PRC Regulation of Healthcare Institutions, hospitals are subject to registration with the health department of the local government to obtain business license for hospital services. We received our renewed business license from Nanning municipal government in November 2007, and this license is valid until November, 2020. Other existing regulations having material effects on our business include regulations dealing with physician's licensing, usage of medicine and injection, and public security in health and medical advertising.

NTH must register with and maintain an operating license from the local health department, due to the fact that NTH currently maintains a facility with over 100 beds. NTH is subject to review by the local health department at least once every three years. If NTH fails to meet their standards, NTH’s business license may be revoked. NTH is also obligated to provide free services or dispatch our physicians or other employees in the event of a need for public assistance. NTH dedicates a very small percentage of its resources to providing free public services.

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements include all of the adjustments, which, in the opinion of management, are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet information as of December 31, 2016 was derived from the audited consolidated financial statements included in the Form 10-K. These condensed consolidated financial statements should be read in conjunction with the audited financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended on December 31, 2016(“Form 10-K”), filed with the Commission on April 18, 2017.

This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the condensed consolidated financial statements and the Form 10-K.

TONGJI HEALTHCARE GROUP, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(UNAUDITED)

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

BASIS OF PRESENTATION AND CONSOLIDATION

These financial statements present the Company’s results of operations, financial position and cash flows on a consolidated basis. The consolidated financial statements include the Company and its wholly owned subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. Our policy is to consolidate all subsidiaries in which a greater than 50% voting interest is owned and all variable interest entities to which we had a variable interest and effectively control the entity. The Company operates in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”.

CASH AND CASH EQUIVALENTS

For purposes of the statements of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. A substantial amount of the Company’s cash is held in bank accounts in the PRC and is not protected by Federal Deposit Insurance Corporation (FDIC) insurance or any other similar insurance. Cash held in China amounted to $42,251 as of March 31, 2017. Given the current economic environment and the financial condition of the banking industry, there is a risk that the deposits may not be readily available or covered by such insurance. The Company has had no loss of cash in domestic or foreign banks in past years.

USE OF ESTIMATES

The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported assets and liabilities, disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of net revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may be material. The more significant estimates and assumptions by management include, among others, useful lives and residual values of fixed assets, valuation of inventories, accounts receivable, stock based compensation, and allowance for bad debt. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

TRANSLATION ADJUSTMENT

The Company's functional currency is the Chinese Renminbi (RMB). The reporting currency is that of the US Dollar. Capital accounts of the consolidated financial statements are translated into United States dollars from RMB at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rates as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the year. The RMB is not freely convertible into foreign currency and all foreign currency exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US dollar at the rates used in translation.

The exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements were as follows:

March 31, 2017
Balance sheet	RMB 6.88 to US $1.00
Statement of income and other comprehensive income	RMB 6.89 to US $1.00

December 31, 2016
Balance sheet	RMB 6.94 to US $1.00
Statement of income and other comprehensive income	RMB 6.64 to US $1.00

March 31, 2016
Balance sheet	RMB 6.45 to US $1.00
Statement of income and other comprehensive income	RMB 6.54 to US $1.00

TONGJI HEALTHCARE GROUP, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(UNAUDITED)

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

RECLASSIFICATIONS

Certain items previously reported under specific financial statement captions have been reclassified to conform to the current year presentation.

REVENUE RECOGNITION

The Company's revenue recognition policies are in compliance with Staff Accounting Bulletin 104 (ASC 605). Service revenue is recognized on the dates services were rendered. When a formal arrangement exists, the price is fixed or determinable. When the service is completed, no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue.

The Company generates revenue from individual patients as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon government established charges. Revenues for pharmaceutical drug sales are recognized upon the drug being administered to a patient.

Patient revenues are recorded based on pre-established rates set by the local government. The Company bills for services provided to Medicare patients through a medical card (the US equivalent of an insurance card). There have not been significant differences between the amounts the Company has billed the government Medicare funds and the amounts collected from the Medicare funds.

ACCOUNTS RECEIVABLE

Accounts receivable are recorded at the estimated net realizable amounts from government fund, insurance companies and patients. Collections have not been considered an area that exposes the Company to additional risk. Hospital staff verifies patient coverage prior to examinations and/or procedures.

For any Medicare patient who visits the hospital and is qualified for acceptance, the hospital will only include the portion that the social insurance organization will pay in the accounts receivable and collects the self-pay portion in cash at the time of service. Management continues to estimate the likelihood of bad debt on an ongoing basis.

The Company has estimated a bad debt allowance of approximately $28,268 as of March 31, 2017 and $28,000 as of December 31, 2016.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company applies the provisions of FASB ASC Topic 825, which requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of March 31, 2017 and December 31, 2016 the fair value of cash and cash equivalents, accounts receivable, other current receivable, accounts payable and accrued expenses, settlement payable, capital lease payable and other payables approximated the carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates except for related party debt or receivables for which it is not practicable to estimate fair value.

FAIR VALUE MEASUREMENTS

FASB ASC Topic 820, “Fair Value Measurements and Disclosures”, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.

Various inputs are considered when determining the fair value of the Company’s investments, and long-term debt. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.

TONGJI HEALTHCARE GROUP, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(UNAUDITED)

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

	·	Level 1 – observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.
	·	Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).
	·	Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments).

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or non-recurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. The Company had no financial assets and liabilities carried at fair value on a recurring basis.

The availability of inputs observable in the market varies from instrument to instrument and depends on a variety of factors including the type of instrument, whether the instrument is actively traded, and other characteristics particular to the transaction. For many financial instruments, pricing inputs are readily observable in the market, the valuation methodology used is widely accepted by market participants, and the valuation does not require significant management discretion. For other financial instruments, pricing inputs are less observable in the market and may require management judgment.

CONCENTRATIONS, RISKS, AND UNCERTAINTIES

All of the Company’s operations are located in the PRC. There can be no assurance that the Company will be able to successfully continue to operate and failure to do so would have a material adverse effect on the Company’s financial position, results of operations and cash flows. In addition, the success of the Company’s operations is subject to numerous contingencies, some of which are beyond management’s control. These contingencies include general economic conditions, the price of medicine, competition, governmental and political conditions, and changes in regulations. Because the Company is dependent on the domestic market of the PRC, the Company is subject to various additional political, economic and other uncertainties. Among other risks, the Company’s operations will be subject to risk of restrictions on the transfer of funds, domestic policy changes, changing taxation policies, foreign exchange restrictions, and political and governmental regulations.

CONTINGENCIES

Certain conditions may exist as of the date the consolidated financial statements are issued. These conditions may result in a future loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

MEDICAL SUPPLIES

Medical supplies include both western and traditional Chinese medicine, are valued on the lower of weighted average cost or market basis. Inventory includes product cost and inbound freight. Management compares the cost of medical supplies with the market value and allowance is made for writing down their inventories to market value, if such value is lower.

TONGJI HEALTHCARE GROUP, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(UNAUDITED)

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

EQUIPMENT

Equipment is recorded at cost. Depreciation is computed over the estimated useful lives of the related asset type using the straight-line method. Maintenance and repairs are expensed as incurred and the costs of additions and betterments that increase the useful lives of the assets are capitalized. When equipment is disposed, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income or expenses.

IMPAIRMENT OF LONG-LIVED ASSETS

The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of FASB Topic ASC 360, “Property, Plant, and Equipment”, and FASB ASC Topic 205 “Presentation of Financial Statements”. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.

The Company tests long-lived assets for recoverability at least annually or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. The Company considers historical performance and future estimated results in its evaluation of potential impairment and then compares the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, the Company measures the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows at the rate the Company utilizes to evaluate potential investments. The Company estimates fair value based on the information available in making whatever estimates, judgments and projections are considered necessary. There was no impairment of long-lived assets for the three months ended March 31, 2017 and 2016.

BASIC AND DILUTED EARNINGS PER SHARE

Earnings per share (EPS) is calculated in accordance with the FASB ASC Topic 260, “Earnings Per Share.” Basic net income (loss) per share is based upon the weighted average number of common shares outstanding. Diluted net income (loss) per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Potentially dilutive securities to purchase 100,000 shares of common stock were not included in the calculation of the diluted earnings per share as their effect would be anti-dilutive for the three months ended March 31, 2017. During the three month period ended March 31, 2017, the average market price of the common stock was less than the exercise price of the stock options and the Company was in net loss position. Accordingly, the stock options were anti-dilutive and have not been included in the calculation of diluted earnings per share.

INCOME TAXES

FASB ASC Topic 740, "Income Taxes” requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

In accordance with ASC Topic 740-10, “Accounting for Uncertainty in Income Taxes — An Interpretation of FASB ASC Topic 740” , which requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.

TONGJI HEALTHCARE GROUP, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(UNAUDITED)

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.

The Company has made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10 and has not recognized any material uncertain tax positions.

In addition, companies in the PRC are required to pay business taxes consisting of 5% of income they derive from providing medical treatment, as well as city construction taxes and educational taxes which are 7% and 3%, respectively, of the business taxes. In April 2010, the Company was granted an exemption from these taxes until further notice from the tax bureau.

The Company had accrued approximately $40,000 under taxes payable account for failure to file US tax returns and Form 5472 between the years 2006 to 2009. The Company is current with its required filings. In addition, the Company does not accrue United States income taxes on unremitted earnings from foreign operations, as it is the Company’s intention to invest these earnings in the foreign operations indefinitely.

STATEMENT OF CASH FLOWS

In accordance with FASB ASC Topic 230, "Statement of Cash Flows," cash flows from the Company's operations are calculated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet.

EMPLOYEE BENEFIT COSTS

The Company contributes to a defined contribution retirement plan organized by the municipal government in the province in which the Company’s subsidiary is registered. The Company makes contributes for qualified employees that are eligible to participate in the plan. Contributions to the plan are calculated at 30% of the employees’ salaries above a fixed threshold amount; employees contribute 8% and the Company’s subsidiary contributes the balance of 22%. The Chinese government is responsible for the benefit liability to retired employees. The Company has no other material obligation for the payment of retirement beyond the annual contribution.

STOCK-BASED COMPENSATION

For purposes of determining the variables used in the calculation of stock compensation expense under the provisions of FASB ASC Topic 505, “Equity” and FASB ASC Topic 718, “Compensation — Stock Compensation,” we perform an analysis of current market data and historical Company data to calculate an estimate of implied volatility, the expected term of the option and the expected forfeiture rate. With the exception of the expected forfeiture rate, which is not an input, we use these estimates as variables in the Black Scholes model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. In addition, any differences between estimated forfeitures and actual forfeitures could also have a material impact on our financial statements.

Stock-based compensation costs that have been included in operating expenses amounted to $0 and $0, for the three month periods ended March 31, 2017 and 2016, respectively.

COMPREHENSIVE INCOME

The Company reports comprehensive income in accordance with FASB ASC Topic 220 “Comprehensive Income," which established standards for reporting and displaying comprehensive income and its components in a financial statement that is displayed with the same prominence as other financial statements.

TONGJI HEALTHCARE GROUP, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(UNAUDITED)

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

Total comprehensive income is defined as all changes in stockholders' equity during a period, other than those resulting from investments by and distributions to stockholders (i.e., issuance of equity securities and dividends). Generally, for the Company, total comprehensive income (loss) equals net income (loss) plus or minus adjustments for currency translation. Total comprehensive income (loss) represents the activity for a period net of related tax and was a loss of $(216,780) and $(140,366) for the three month periods ended March 31, 2017 and 2016, respectively.

While total comprehensive income is the activity in a period and is largely driven by net earnings in that period, accumulated other comprehensive income or loss (“AOCI”) represents the cumulative balance of other comprehensive income as of the balance sheet date. For the Company, AOCI is primarily the cumulative balance related to the currency adjustments and increased overall equity by $533,917and $587,508 as of March 31, 2017 and December 31, 2016, respectively.

RECENT ACCOUNTING PRONOUNCEMENTS

Recent accounting pronouncements issued by the FASB, the AICPA and the SEC did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.

GOING CONCERN

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has negative working capital of $6,947,247, an accumulated deficit of $7,369,605, and a stockholders’ deficit of $6, 379,508 as of March 31, 2017. The Company’s ability to continue as a going concern ultimately is dependent on the management’s ability to obtain equity or debt financing, attain further operating efficiencies, and achieve profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company not be able to continue as a going concern.

Management has taken certain restructuring steps to provide the necessary capital to continue its operations. These steps included: 1) disposal of the construction-in-progress new hospital. 2) plan to convert existed related parties’ loans into equity, 3) plan to increase sales revenue with additional medical equipment, No assurances can be given that the steps taken will provide necessary capital for the Company to continue its operations.

NOTE 3- EQUIPMENT

Equipment as of March 31, 2017 and December 31, 2016 comprised the following:

	Estimated Useful Lives (Years)	March 31, 2017 (Unaudited)	December 31, 2016
Office equipment	5-10	$78,261	$77,587
Medical equipment	5	1,251,452	1,240,674
Capital lease equipment	5	1,635,064	1,620,982
Fixtures	10	102,936	102,049
Vehicles	5	40,453	40,104
Total equipment		3,108,166	3,081,396

Less accumulated depreciation		(1,359,129)	(1,329,569)
Less impairment of the equipment		1,377,533)	(1,365,669)
Property and equipment, net		$371,504	$386,158

Depreciation expense charged to operations was $20,254 and $17,977 for the three months periods ended March 31, 2017 and 2016.

TONGJI HEALTHCARE GROUP, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(UNAUDITED)

NOTE 4- OTHER CURRENT RECEIVABLE

In March 2016, Nanning Tongji Hospital, Inc. sold its construction in progress hospital building to Guangxi Yida Friendship Hospital Management, Inc. for RMB 86,000,000 (approximately $13,000,000). As of the date of disposal, we had accrued approximately $15,000,000 for the construction of the hospital. As a result of the sale, we increased other receivables to approximately $13,000,000. Concurrently, the remaining balance results in an extraordinary loss in the approximate amount of $2,000,000 in 2016. As of March 31, 2017, we received payment of approximately $5,400,000, whereas no payment received during first quarter of 2017. The remaining balance of other current receivable is $7,305,954 as of March 31, 2017.

NOTE 5- LAWSUIT SETTLEMENT PAYABLE

In September 2009, Guangxi Nanning Tingyouyuxiang Commercial Co., Ltd. (“Tingyouyuxiang”) filed a civil suit against Nanning Tongji Hospital, Inc. (“NTH”), a subsidiary of the Company in the People’s Court. In the complaint, Tingyouyuxiang asserted a breach of contract claim against NTH, alleging that NTH had failed to make timely and total payment of RMB 5,050,000 (approximately $800,000) under certain Supplement Agreement by and among NTH, Tingyouyuxiang and the Eighth Group of Langdong Village Committee, Nanhu Community Office, Qingxiu District, Nanning City (the “Village Committee”). On December 30, 2009, the People’s Court ruled that NTH shall pay to Tingyouyuxiang damages of RMB 5,050,000 (approximately $800,000) plus interest and the court hearing fee approximately $320,000. On March 9, 2012, NTH appealed to the Intermediate Court in Nanning City, alleging, among other things, that NTH was never served. On June 6, 2012, the Intermediate Court remanded the case to the People’s Court. On June 20, 2013, the People’s Court dismissed the action. On October 21, 2013, NTH appealed the dismissal to the Intermediate Court and the Intermediate Court accepted the appeal on October 21, 2013. On April 16, 2014, the Intermediate Court dismissed NTH appeal and affirmed the decision of the People’s Court. Upon settlement of the lawsuit, the Company had accrued approximately $1,399,980 settlement payable as of March 31, 2017.

NOTE 6- MAJOR SUPPLIERS AND CUSTOMERS

The Company purchases the majority of its medicine supplies from Guangxi Liuzhou Medicine Co., Ltd., which accounted for 44% and 6% of all medicine purchases for three month periods ended March 31, 2017 and 2016. The rest are from around 13 different suppliers.One of the suppliers, Guangxi Tongji Medicine Co. Ltd., a related company that our Chief Executive Officer controls accounted for 0% and 5% of all medicine purchases for the three month periods ended March 31, 2017 and 2016.

The Company had two major customers for the three month periods ended March 31, 2017 and 2016: Nanning Social Insurance Center accounted for 53% and 47% of revenue for the three month periods ended March 31, 2017 and 2016, respectively. China UMS accounted for 10% and 14% of revenue for the three month periods ended March 31, 2017 and 2016, respectively. As of March 31, 2017, accounts receivable due from Nanning Social Insurance Center and China UMS was approximately $199,369 and $309, respectively. The Company has estimated a bad debt allowance of approximately $28,268 as of March 31, 2017 and $28,000 as of December 31, 2016.

NOTE 7- CAPITAL LEASE OBLIGATIONS

Sale and Lease Back

On March 25, 2011, the Company completed a financing arrangement with an independent third party to sell and leaseback certain machinery and equipment. The net carrying value of the machinery and equipment sold was $262,683. The machinery and equipment was sold for $371,517, of which $334,365 was received in cash and $37,152 was held as refundable deposit. The transaction has been accounted for as a financing arrangement, wherein the property remains on the Company’s books and will continue to be depreciated. A financing obligation in the amount of $371,517, representing the proceeds, has been recorded under “Capital Lease Payable” in the Company’s Balance Sheet, and is being reduced based on payments under the lease. The lease was not completed as no payment was made in 2016 and first quarter of 2017. As of March 31, 2017, lease payable was approximately $100,000.

TONGJI HEALTHCARE GROUP, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(UNAUDITED)

NOTE 7- CAPITAL LEASE OBLIGATIONS - continued

In October 2011, the Company entered into an agreement to lease certain machinery and equipment that are classified as capital leases. The cost of equipment under capital leases of approximately $1,430,000 is included in the Balance Sheet as property, plant, and equipment at December 31, 2016. Those equipment are to be placed in service upon usage approval from the Chinese government and hiring qualified personnel. As of March 31, 2017, the Company still has not received the approval. Accumulated impairment loss of the leased equipment at March 31, 2017 was approximately $1,377,533. Capital Lease Payable was approximately $425,000 including accrued interest payable of approximately $30,000 as of March 31, 2017.

NOTE 8- OTHER PAYABLE

Other payable as of March 31, 2017 and December 31, 2016 consists of the following:

	March 31, 2017 (Unaudited)	December 31, 2016
Advance from customers	$0	$555
Accrued Salary	53,590	53,128

Tax payable	699,864	694,039
Accrued Professional Expenses	434,139	387,160
Unemployment & Retirement Insurance Payable	33,475	27,133
Deposit Payable	31,401	31,131
Employees Training Fees Payable	16,275	16,135
Rent Deposit Payable	5,102	5,058
Other Payable	44,863	54,837
Total	$1,318,709	$1,269,176

In March 2016, Nanning Tongji Hospital, Inc. sold its construction in progress hospital building to Guangxi Yida Friendship Hospital Management, Inc. for RMB 86,000,000 (approximately $13,000,000). We incurred value-added tax (VAT) and other taxes liability of RMB 4,530,000 (approximately $658,124) related to this transaction in tax payable account.

NOTE 9- STOCKHOLDERS' DEFICIT

Preferred Stock

As of March 31, 2017 and December 31, 2016, the Company has 20,000,000 shares of preferred stock authorized with a par value of $0.001. There are no shares issued and outstanding as of March 31, 2017.

Common Stock

As of March 31, 2017 and December 31, 2016, the Company has 50,000,000 shares of common stock authorized with a par value of $0.001 and 15,812,191 shares issued and outstanding.

Statutory Reserves

As stipulated by the Company Law of the PRC, net income after taxation can only be distributed as dividends after appropriation has been made for the following:

i.	Making up cumulative prior years’ losses, if any;

ii.	Allocations to the “Statutory surplus reserve” of at least 10% of income after tax, as determined under PRC accounting rules and regulations, until the fund amounts to 50% of the Company’s registered capital;

iii.	Allocations to the discretionary surplus reserve, if approved in the stockholders’ general meeting.

TONGJI HEALTHCARE GROUP, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(UNAUDITED)

NOTE 9- STOCKHOLDERS' DEFICIT - continued

As of March 31, 2017, the Company had accumulated deficits of $7,369,605. Therefore, the Company did not appropriate any fund for the statutory surplus reserve for the three month period ended March 31, 2017.

Stock Option

No stock-based compensation recorded for the three months periods ended March 31, 2017 and 2016, respectively.

On March 3, 2011, an option to purchase 100,000 shares of common stock was granted to the Company’s CFO. The option vests in three equal installments starting on the first anniversary of grant and subsequent anniversaries thereafter, at an exercise price equivalent to the closing price per share of common stock on the date of grant.

The fair value of the option award is estimated on the date of grant using the Black Scholes model to be $15,400. The valuation was based on the assumptions noted in the following table.

Expected volatility		105 %
Expected Dividends		0 %
Stock price		$ 0.24
Expected term (in years)		3 years
Risk-free rate		1.32 %

The risk-free interest rate is based on the U.S. Treasury yield curve in effect for the expected term of the option at the time of grant. The dividend yield on our common stock is assumed to be zero since we do not pay dividends and have no current plans to pay them in the future. The market price volatility of our common stock was based on historical volatility since May 13, 2010. The expected life of the options is based upon our anticipated expectations of exercise behavior since no options have been exercised in the past to provide relevant historical data.

The following table summarizes stock option activity in the Company's stock-based compensation plans for the three month period ended March 31, 2017.

Number of Shares		Weighted Average Exercise Price	Aggregate Intrinsic Value (in thousands)
Outstanding at January 1, 2017	100,000	$0.24	$-
Granted	-	-	-
Exercised	-	-	-
Cancelled/expired	-	-	-
Outstanding and exercisable at March 31, 2017	100,000	$0.24	$-

There were no options granted, exercised or cancelled/expired during the three month period ended March 31, 2017.

NOTE 10- RELATED PARTY TRANSACTIONS AND COMMITMENTS

Due from/to Related Parties

The Company has entered into agreements with Nanning Tongji Chain Pharmacy Co. Ltd., Guangxi Tongji Medicine Co. Ltd., and Nanning Switch Factory whereby the Company from time to time will advance funds to assist them with their operations. The three companies have common major stockholders. The advanced amounts accrue interest at a rate of 1.5% per annum. The amount receivable as of March 31, 2017 and December 31, 2016 was $48,565 and $48,145, respectively. Interest income for the three month periods ended March 31, 2017 and 2016 were approximately $182 and $159, respectively.

TONGJI HEALTHCARE GROUP, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2017

(UNAUDITED)

NOTE 10- RELATED PARTY TRANSACTIONS AND COMMITMENTS - continued

The Company has entered into an agreement with the Chairman and a stockholder of the Company, Nanning Tongji Chain Pharmacy Co. Ltd., Guangxi Tongji Medicine Co. Ltd., and Nanning Tongji Electric Coating Factory, whereby the Company from time to time will be advanced funds to for its operations. The advanced amounts accrue interest at a rate of 1.5% per annum. As of March 31, 2017 and December 31, 2016, $12,111,543 and $12,005,569 were payable to these related parties, respectively. Interest expenses for the three month periods ended March 31, 2017 and 2016 were $57,000 and $67,485, respectively.

Rental Commitments

On March 1, 2015, the Company renewed the lease agreement for their hospital with Guangxi Tongji Medicine Co. Ltd that expires in December 2014. Monthly lease payment under the new lease is approximately $4,800. The lease will expire on February 28, 2018. Based on the exchange rate at March 31, 2017, minimum future lease payments are as follows:

	Related Party	Total
2017	$39,226	$39,226
2018	8,717	8,717
Total	$47,943	$47,943

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our condensed consolidated financial statements and the related condensed notes included elsewhere in this report. Our financial statements have been prepared in accordance with U.S. GAAP. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements.

Overview

Nanning Tongji Hospital, Inc. ("NTH" or “Tongji Hospital”) was established in Nanning city Guangxi province of the Peoples’ Republic of China ("PRC") by the Guangxi Tongji Medical Co. Ltd. and an individual on October 30, 2003.

NTH is a designated hospital for medical insurance in city of Nanning and Guangxi province. NTH specializes in the areas of internal medicine, surgery, gynecology, pediatrics, emergency medicine, ophthalmology, medical cosmetology, rehabilitation, dermatology, otolaryngology, traditional Chinese medicine, medical imaging, anesthesia, acupuncture, physical therapy, health examination, and prevention.

On December 27, 2006, we, through our wholly-owned subsidiary, Tongji, Inc., a Colorado company, acquired 100% of the equity in NTH pursuant to an Agreement and Plan of Merger. We issued 15,652,557 shares of common stock to the shareholders of NTH in exchange for 100% of the issued and outstanding shares of NTH. Accordingly, NTH became a wholly owned subsidiary of Tongji, Inc. We have been in the business of operating hospitals and providing healthcare services in Nanning, Guangxi province of the PRC.

The acquisition of NTH was accounted for as a reverse acquisition under the purchase method of accounting since the shareholders of NTH obtained control of the consolidated entity. Accordingly, the reorganization of the two companies was recorded as a recapitalization of NTH. We treated NTH as the continuing operating entity. We have two sources of operating revenues: in-patient service revenues and out-patient service revenues. In addition to provide services to our patients, we also sell pharmaceutical drugs to our patients. Revenues from such sales are included in either our in-patient service revenues or our out-patient service revenues. Our revenues come from individuals as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon local government established charges. Revenues are recorded at estimated net amounts due from patients or third-party payers. Revenues from pharmaceutical drug sales are recognized upon the drug being administered to a patient or at the time a prescription by a registered physician is filled.

Patient revenues are recorded based on pre-established rates set by the local government. The Company bills for services provided to Medicare patients through a medical card (the US equivalent of an insurance card). Historically, there have been no significant differences between the amounts the Company has billed the government Medicare funds and the amounts collected from the Medicare funds.

The Company had two major customers for the three month period ended March 31, 2017 and 2016: Nanning Social Insurance Center and China UMS. Nanning Social Insurance Center accounted for 53% and 47% of revenue for the three month period ended March 31, 2017 and 2016, respectively. China UMS accounted for 10% and 14% of revenue for the three month period ended March 31, 2017 and 2016, respectively.

The Company purchases the majority of its medicine supplies from two suppliers which collectively accounted for more than 57% of our total purchases for the three month period ended March 31, 2017. The rest are from around 12 different suppliers. One of the former suppliers, Guangxi Tongji Medicine Co. Ltd., is a related company that our Chief Executive Officer controls and accounted for 0% of our total purchases for the three month period ended March 31, 2017.

In March 2016, we sold our construction-in-progress hospital building to Guangxi Yida Friendship Hospital Management, Inc. for RMB 86,000,000 (approximately $13,000,000). The hospital building is being constructed by Guangxi Construction Engineering Corporation Langdong 8th Group (“Langdong 8th Group”). Costs capitalized primarily consists of payments for construction costs, acquisition cost, land rights cost, development expenditure, professional fees, and capitalized interest. As of the date of disposal, we had accrued approximately $15,000,000 for the construction of the hospital. As a result of the sale, we increased the other receivables to approximately $13,000,000. Concurrently, the remaining balance results in an extraordinary loss in the approximate amount of $2,000,000 in 2016. As of March 31, 2017, we received payment amount of $5,400,000, whereas no payment received during the first quarter of 2017. We incurred value-added tax (VAT) and other taxes liability of RMB 4,530,000 (approximately $658,124) related to this transaction. The amount is included in other payables.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued

Difference in the Medical System between the U.S. and China

In the United States most hospitals have contracts with health insurance companies that provide reduced rates for healthcare services for patients with health insurance. Medicare and Medicaid patients, also, receive reduced rates. Functionally, the patient is billed for health services at the higher rate normally charged to patients without insurance. The amount billed is then reduced by the charges paid by the insurance carrier and by the difference (sometimes known as the "contractual allowance") between the normal rate for the services and the reduced rate that the hospital estimates it will receive from Medicare, Medicaid an d insurance companies.

For financial reporting purposes, hospitals in the United States record revenues based upon established billing rates less adjustment for contractual allowances. Revenues are recorded based upon the amounts due from the patients and third-party payers, including federal and state agencies (under the Medicare and Medicaid programs) managed care health plans, health insurance companies, and employers. Estimates of contractual allowances under third-party payer arrangements are based upon the payment terms specified in the related contractual agreements. Third-party payer contractual payment terms are generally based upon predetermined rates per diagnosis, per diem rates, or discounted fee-for-service rates.

Due to the complexities involved in determining amounts ultimately due under reimbursement arrangements with a large number of third-party payers, which are often subject to interpretation, the reimbursement actually received by U.S. hospitals for health care services is sometimes different from their estimates.

The medical system in the PRC is different from that in the United States. Private medical insurance is not generally available to the PRC’s population and as a result services and medications provided by our hospital are usually paid by cash or by the Medicare agencies of the Nanning municipal government and the Guangxi provincial government. Our billing system automatically calculates the reimbursements that we are entitled to base upon regulations promulgated by theses government agencies. We bill the Medicare agencies directly for services provided to patients covered by these Medicare programs. In addition, due to the fact that rates are established by the government, there is no difference between rates for patients covered by Medicare and patients who pay cash.

Since we only deal with the Nanning municipal and the Guangxi provincial Medicare agencies, we are familiar with their regulations pertaining to reimbursements. As a result, there is normally no material difference between the amounts we bill and the amounts we receive for services provided to Medicare patients.

Results of Operation - Three Months Ended March 31, 2017 and 2016

Material changes of items in our Statement of Operations for the three months ended March 31, 2017, as compared to the three months ended March 31, 2016, are discussed below.

Operating Revenues – Operating revenue for the three month period ended March 31, 2016, which resulted primarily from in-patient services and out-patient services, was $338,396, a decrease of $163,270 or 33%, as compared with the operating revenue of $501,666 for the same period of 2016. Our in-patient service revenue was $194,626 for the three month period ended March 31, 2017, as compared to $257,902 for the same period in 2016, a decrease of $63,276 or 25%. The decrease in the in-patient service revenue was primarily due to reduced revenue from our in-patient ophthalmology department.. Our out-patient service revenue was $143,770 for the three month period ended March 31, 2017, a decrease of $99,994 or 41% as compared to $243,764 for the same period in 2016. The decrease in the out-patient service revenue was primarily due to the closure of personnel medical care department and resignation of doctors from our out-patient department since second quarter of 2016, resulting in fewer patients being treated.

Operating Expenses – Operating expenses were $419,176 for the three month period ended March 31, 2017, a decrease of 24% as compared to $553,607 for the same period of 2016, which is in line with the decrease in our operating revenues.

Loss from Operations - Operating loss was $80,780 for the three month period ended March 31, 2017, an increase of $28,839 or56% as compared to an operating loss of $51,941 for the same period of 2016. The primary reason for the increase in loss from operations is the decline in operating revenues.

Interest Expense – Interest expense for the three month period ended March 31, 2017 was $88,858 as compared to $80,815 for the three month period ended March 31, 2016, a slight increase of $8,043 or10%.

Net Loss - As a result of the forgoing, the Company had a net loss of $163,189 during the quarter ended March 31, 2017, compared to a net loss of $125,305 for the comparative period in 2016, an increase of $37,884 or 30%.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued

Trends, Events and Uncertainties

The China Ministry of Health, as well as other related agencies, has proposed changes to the prices we can charge for medical services, drugs and medications. We cannot predict the impact of these proposed changes since the changes are not fully defined and we do not know whether those proposed changes will ever be implemented or when they may take effect.

In March 2016, Nanning Tongji Hospital, Inc. sold its construction in progress hospital building to Guangxi Yida Friendship Hospital Management, Inc. for RMB 86,000,000 (approximately $13,000,000). The hospital building is being constructed by Guangxi Construction Engineering Corporation Langdong 8th Group (“Langdong 8th Group”). Costs capitalized primarily consists of payments for construction costs, acquisition cost, land rights cost, development expenditure, professional fees, and capitalized interest. As of the date of disposal, we had accrued approximately $15,000,000 for the construction of the hospital. As a result of the sale, we increased other receivables by approximately $13,000,000. Concurrently, the remaining balance results in an extraordinary loss of approximately $2,000,000 in 2016. As of March 31, 2017, we have received payment of approximately $5,400,000. We incurred value-added tax (VAT) and other taxes liability of RMB 4,530,000 (approximately $658,124) related to this transaction. The amount is included in other payable.

We plan to acquire other hospitals and companies involved in the healthcare industry in the PRC using cash and shares of our common stock. Substantial capital may be needed for these acquisitions and we may need to raise additional funds through the sale of our common stock, debt financing or other arrangements. We do not have any commitments or arrangements from any person to provide us with any additional capital. Additional capital may not be available to us, or if available, on acceptable terms, in which case we would not be able to acquire other hospitals or businesses in the healthcare industry.

Other than the factors listed above, we do not know of any trends, events or uncertainties that have had or are reasonably expected to have a material impact on our net sales or revenues or income from continuing operations. Our business is not seasonal in nature.

Accounting Estimates

In the United States most hospitals have contracts with health insurance companies that provide reduced rates for healthcare services for patients with health insurance. Medicare and Medicaid patients also receive reduced rates. Functionally, the patient is billed for health services at the higher rate normally charged to patients without insurance. The amount billed is then reduced by the charges paid by the insurance carrier and by the difference (sometimes known as the "contractual allowance") between the normal rate for the services and the reduced rate that the hospital estimates it will receive from Medicare, Medicaid and insurance companies.

The medical system in the PRC is different from that in the United States. Private medical insurance is not generally available to the PRC’s population and as a result services and medications provided by our hospital are usually paid for in cash or by the Medicare agencies of the Nanning municipal government and the Guangxi provincial government. Our billing system automatically calculates the reimbursements that we are entitled to base upon regulations promulgated by theses government agencies. We bill the Medicare agencies directly for services provided to patients covered by theses Medicare programs. In addition, due to the fact that rates are established by the government, there is no difference between rates for patients covered by Medicare and patients who only use cash.

Since we only deal with the Nanning municipal and the Guangxi provincial Medicare agencies we are familiar with their regulations pertaining to reimbursements. As a result, there is normally no material difference between the amounts we bill and the amounts we receive for services provided to Medicare patients.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued

Liquidity and Capital Resources

We generally finance our operations through our operating profits and borrowings from related parties. As of the date of this report, we have not experienced any difficulty in raising funds from related parties, and we have not experienced any liquidity problems in settling our payables in our ordinary course of business. We believe that we have adequate funds and capital with respect to conducting its business over the next twelve months.

The following shows our material sources and uses of cash during the three month periods ended March 31, 2017 and 2016:

	2017 (Unaudited)	2016 (Unaudited)
Cash provided by (used in) operating activities	$(43,698)	$18,660

Cash (used in) investing activities	$0	$(50,957)

Cash provided by financing activities	$37,940	$64,339

The Company carefully monitors and controls the amount of cash used to fund operating activities. However, substantial funds are required to fund the lawsuit settlement (see Note 5 to the Financial Statements accompanying this Report). Financing of operations has come primarily from advances from related parties. We are dependent on related parties to provide working capital and pay our management team until such time as our operations are profitable. There can be no assurances that related parties will continue to provide additional capital. Without additional capital, we may be forced to cease operations and liquidate.

Operating Activities

Net cash used in operating activities primarily consists of net loss, as adjusted by depreciation, stock option, and changes in non-cash working capital items such as accounts receivable, medical supplies, capital lease deposits, prepaid expense and other current assets, accounts payables and accrued liabilities , and other payables.

Net cash used in operating activities was $43,698 for the three months ended March 31, 2017, a decrease of $62,358 or 334% as compared with the net cash provided by operating activities of $18,660 for the same period in 2016. The decrease in net cash provided in operating activities was primarily due to the reduced revenue, resulting in a $37,884 increase in net loss.

Investing Activities

Net cash used in investing activities was $0for the three months ended March 31, 2017, a decrease of $50,957 or 100%, as compared with the net cash used in investing activities of $50,957 for the same period in 2016. The decrease in net cash used in investing activities was primarily due to disposal of construction in progress in 2016, resulting reduced cash contribution in the current period.

Financing Activities

Net cash provided by financing activities primarily consists of proceeds from related party loans.

Net cash provided by financing activities was $37,940 for the three months ended March 31, 2017, a decrease of $26,399 or 41%, as compared with the net cash provided by financing activities of $64,339 for the same period in 2016. The decrease was primarily attributable to decrease in funds advanced by related parties due to disposal of construction in progress.

Working Capital

Our working capital was negative $6,947,247 as of March 31, 2017, as compared with negative $6,745,663 as of December 31, 2016, a decrease of $201,584, which is primarily attributable to the increase in related party loans of approximately $128,054, decrease in accounts receivable of approximately $48,778 and increase in other payables of approximately $49,533.

Rental Commitments

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. - continued

	Related Party	Total
2017	$39,226	$39,226
2018	8,717	8,717
Total	$47,943	$47,943

Going Concern

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has negative working capital of $6,947,247, an accumulated deficit of $7,369,605, and a stockholders’ deficit of $6,379,508as of March 31, 2017. The Company’s ability to continue as a going concern ultimately is dependent on the management’s ability to obtain equity or debt financing, attain further operating efficiencies, and achieve profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company not be able to continue as a going concern.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet items reasonably likely to have a material effect on our financial condition.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls

Our management maintains disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to provide reasonable assurance that the material information required to be disclosed by us in our periodic reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

As of March 31, 2017, our management, under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as required by Rules 13a-15(b) and 15d-15(b) under the Exchange Act. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of March 31, 2017 as a result of the material weaknesses identified in our internal control over financial reporting, which are discussed below. Our management considers our internal control over financial reporting to be an integral part of our disclosure controls and procedures.

Specifically, our management identified certain matters involving internal control and our operations that it considered to be material weaknesses. As defined in the Exchange Act, a material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the registrant's annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified by our management as of March 31, 2017, are described below:

Item 4. Controls and Procedures. - continued

●

We did not design, implement, or maintain effective entity-level controls related to our control environment, resulting in the following significant control deficiencies:

The Code of Business Conduct and Ethics, which was specifically designed for public company applicability, has yet to be formally acknowledged by members of management and the finance department.

There is an absence of independence and financial expertise on the Board of Directors, and we do not have an Audit Committee or a formalized internal audit function, limiting its ability to provide effective oversight of our management.

The full implementation of, and related training for, our newly-formalized IT policies and procedures were still in process at year-end. Accordingly, we lacked sufficiently-trained personnel to provide for adequate segregation of duties within the accounting system and effective oversight of controls over access, change, data, and security management.

Our management believes that the pervasive nature of these control deficiencies, when aggregated, impact all significant accounts and disclosures and rise to the level of material weakness.

2017 Planned Remediation

As financial conditions permit, we plan to take the following actions to improve our internal control over financial reporting.

●

Require all members of our management and the finance department across all corporate entities to certify receipt of the revised Code of Business Conduct and Ethics by signature. Signed copies will be retained by our management. Thereafter, our management plans to periodically require signatories to acknowledge that they understand the contents of the Code of Business Conduct and Ethics, and whether they are aware of anyone in our Company that might have violated some part of the Code.

●

Recruit an independent financial expert to the Board of Directors to chair an Audit Committee and formalize roles and responsibilities over our internal control over financial reporting for the Board and our management. Our management also plans to develop and implement a formal corporate internal audit capability, reporting directly to an independent Audit Committee, to provide effective oversight of our internal control over financial reporting.

●

Continue to engage the services of qualified consultants with China GAAP, U.S. GAAP and SEC reporting experience to support our financial reporting and SOX compliance requirements, including assistance with the following:

Remediating identified material weaknesses;

Monitoring our internal control over financial reporting on an ongoing basis;

Managing our period-end financial closing and reporting processes; and

Identifying and resolving non-routine or complex accounting matters.

●

Complete the implementation of, and related training for, its IT policies and procedures related to access, change, data, and security management to ensure that all relevant financial information is secure, identified, captured, processed, and reported within the accounting system and spreadsheets supporting financial reporting.

●

Continue providing training to accounting personnel regarding our significant policies and procedures related to accounting, finance, and internal control to ensure that financial reporting competencies are strengthened.

Our management will continue to monitor and evaluate the effectiveness of its disclosure controls and procedures, as well as its internal control over financial reporting, on an ongoing basis, and is committed to taking further action and implementing additional improvements, as necessary and as funds allow. However, our management cannot guarantee that the measures taken or any future measures will remediate the material weaknesses identified or that any additional material weaknesses or significant deficiencies will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting.

Item 4. Controls and Procedures. - continued

Notwithstanding the material weaknesses described above, our management believes that there are no material inaccuracies or omissions of material fact and, to the best of its knowledge, believes that the consolidated financial statements included in this annual report present fairly, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States.

Changes in Internal Control over Financial Reporting

No changes in the Company's internal control over financial reporting has come to management's attention during the Company's first quarter ended March 31, 2017 that have materially affected, or are likely to materially affect, the Company's internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

In September 2009, Guangxi Nanning Tingyouyuxiang Commercial Co., Ltd. (“Tingyouyuxiang”) filed a civil suit against Nanning Tongji Hospital, Inc. (“NTH”), a subsidiary of the Company in the People’s Court. In the complaint, Tingyouyuxiang asserted a breach of contract claim against NTH, alleging that NTH had failed to make timely and total payment of RMB 5,050,000 (approximately $800,000) under certain Supplement Agreement by and among NTH, Tingyouyuxiang and the Eighth Group of Langdong Village Committee, Nanhu Community Office, Qingxiu District, Nanning City (the “Village Committee”). One December 30, 2009, the People’s Court ruled that NTH shall pay to Tingyouyuxiang damages of RMB 5,050,000 (approximately $800,000) plus interest and the court hearing fee approximately $320,000. On March 9, 2013, NTH appealed to the Intermediate Court, alleging, among other things, that NTH was never served. On September 6, 2013, the Intermediate Court remanded the case to the People’s Court. On April 16, 2014, the Intermediate Court dismissed Tingyouyuxiang’s appeal and affirmed the decision of the People’s Court. Upon settlement of the lawsuit, the Company had accrued approximately $1,399,980 in settlement payable as of March 31, 2017.

Item 1A. Risk Factors.

Not Applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.

Exhibit No.	Title of Document
31.1	Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2	Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1	Certification of the Principal Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **
32.2	Certification of the Principal Financial Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **
101.INS	XBRL Instance Document*
101.SCH	XBRL Taxonomy Extension Schema Document*
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document*
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document*
101.LAB	XBRL Taxonomy Extension Label Linkbase Document*
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document*

* Filed herewith.

** Furnished herewith.

(1) Incorporated by reference to the same exhibit filed with our registration statement on Form SB-2 (File No. 333-140645).

SIGNATURES

Pursuant to the requirements of the securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TONGJI HEALTHCARE GROUP, INC.

Date: May 19, 2017	By:	/s/ Yunhui Yu
		Yunhui Yu President and Chief Executive Officer (Principal Executive Officer)

Date: May 19, 2017	By:	/s/ Eric Zhang
		Eric Zhang Chief Financial Officer (Principal Financial Officer)

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 13, 2017
Document And Entity Information
Entity Registrant Name	Tongji Healthcare Group, Inc.
Entity Central Index Key	0001389518
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		15,812,191
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2017

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Stockholders equity:
Preferred stock, par value	$ 0.001	$ .001
Preferred stock, authorized shares	20,000,000	20,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value	$ 0.001	$ .001
Common stock, authorized shares	50,000,000	50,000,000
Common stock, issued shares	15,812,191	15,812,191
Common stock, outstanding shares	15,812,191	15,812,191

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Cash and cash equivalents	$ 42,251	$ 42,841	$ 47,597	$ 10,300
Estimated bad debt allowance	$ 28,268		28,000
Dilutive securities not included in the calculation of the diluted earnings per share	100,000
Stock-based compensation costs	$ 0	0
Comprehensive Income (Loss)	(216,780)	$ (140,366)
Accumulated other comprehensive income	533,917		587,508
Working capital	(6,947,247)
Accumulated deficit	(7,369,605)		(7,206,416)
Stockholders deficit	$ (6,379,508)		$ (6,162,728)

3. EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
3. EQUIPMENT (Details Narrative) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 20,254	$ 17,977

5. LAWSUIT SETTLEMENT PAYABLE (Details Narrative)	Mar. 31, 2017 USD ($)
Lawsuit Details Narrative
Accrued settlement payable	$ 1,399,980


Date : May 19, 2017	By:	/s/ Yunhui Yu
		Yunhui Yu
		President and Chief Executive Officer (Principal Executive Officer)



Date: May 19, 2017	By:	/s/ Eric Zhang
		Eric Zhang
		Chief Financial Officer (Principal Financial Officer)

Dated: May 19, 2017				/s/ Yunhui Yu
				Yunhui Yu President and Chief Executive Officer (Principal Executive Officer)

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current Assets
Cash	$ 42,251	$ 47,597
Accounts receivable, net	190,599	239,377
Due from related parties	186,975	185,365
Other current receivable	7,305,954	7,243,028
Medical supplies	16,289	52,357
Prepaid expenses and other current assets	13,201	13,087
Total Current Assets	7,755,269	7,780,811
Equipment, net	371,504	386,158
Deposit	172,966	171,476
Intangible assets, net	23,269	25,301
TOTAL ASSETS	8,323,008	8,363,746
Current Liabilities
Accounts payable and accrued expenses	957,616	997,040
Due to related parties	10,499,289	10,371,235
Other payable	1,318,709	1,269,176
Settlement payable	1,399,980	1,366,639
Short-term loan	0	0
Current portion of capital lease payable	526,922	522,384
Total Current Liabilities	14,702,516	14,526,474
Total Liabilities	14,702,516	14,526,474
STOCKHOLDERS' DEFICIT
Preferred stock; $0.001 par value, 20,000,000 shares authorized and none issued and outstanding	0	0
Common stock; $0.001 par value, 50,000,000 shares authorized and 15,812,191 shares issued and outstanding as of March 31, 2017 anf December 31, 2016, respectively	15,812	15,812
Additional paid in capital	440,368	440,368
Accumulated deficit	(7,369,605)	(7,206,416)
Accumulated other comprehensive income	533,917	587,508
Total Stockholders' Deficit	(6,379,508)	(6,162,728)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 8,323,008	$ 8,363,746

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
OPERATING REVENUE
In-patient service revenue	$ 194,626	$ 257,902
Out-patient service revenue	143,770	243,764
Total operating revenue	338,396	501,666
OPERATING EXPENSES
Administrative expenses	65,229	45,916
Depreciation and amortization expenses	20,254	17,977
Medicine and supplies	144,050	241,302
Other operating expenses	49,749	73,253
Salary and fringes	139,894	175,159
Total operating expenses	419,176	553,607
LOSS FROM OPERATIONS	(80,780)	(51,941)
OTHER INCOME (EXPENSE)
Other income	6,449	7,451
Interest expense, net	(88,858)	(80,815)
Total Other Expense	(82,409)	(73,364)
LOSS BEFORE INCOME TAXES	(163,189)	(125,305)
Provision for income taxes	0	0
NET LOSS	(163,189)	(125,305)
OTHER COMPREHENSIVE INCOME
Foreign currency translation gain	(53,591)	(15,061)
NET COMPREHENSIVE LOSS	$ (216,780)	$ (140,366)
Net loss per common stock-Basic and Diluted	$ (0.014)	$ (0.009)
Weighted average common stock outstanding
Basic and Diluted	15,812,191	15,812,191

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities:
Net Loss	$ (163,189)	$ (125,305)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	20,254	17,977
Increase/(decrease) in operating assets and liabilities:
Accounts receivable	50,842	40,600
Medical supplies	36,511	80,301
Prepaid expense and other current assets	(2)	(1,921)
Other receivable	2	(2,384)
Accounts payable and accrued expenses	(48,072)	(41,955)
Other payables	38,495	28,243
Contingent liability	21,461	23,104
Net Cash Used in Operating Activities	(43,698)	18,660
Investing activities:
Acquisitions of fixed assets	0	(6,641)
Construction in progress	0	(44,316)
Net Cash Used in Investing Activities	0	(50,957)
Financing activities:
Due to related parties	37,940	64,339
Net Cash Provided by Financing Activities	37,940	64,339
Effects of Exchange Rate Changes in Cash and Cash Equivalents	412	499
Net increase (decrease) in Cash	(5,346)	32,541
Cash-Beginning of Period	47,597	10,300
Cash-Ending of Period	42,251	42,841
Cash Paid During the Year for:
Income taxes	0	0
Interest paid	$ 6,570	$ 4,756

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
RMBMember \| StatementOfIncomeAndOtherComprehensiveIncomeMember
Exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements	6.89	6.64	6.54
USDollarMember \| StatementOfIncomeAndOtherComprehensiveIncomeMember
Exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements	1.00	1.00	1.00
BalanceSheetMember \| RMBMember
Exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements	6.88	6.94	6.45
BalanceSheetMember \| USDollarMember
Exchange rates used to translate amounts in RMB into USD for the purposes of preparing the financial statements	1.00	1.00	1.00

3. EQUIPMENT (Details) - USD ($)	3 Months Ended
3. EQUIPMENT (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Office equipment	$ 78,261	$ 77,587
Medical equipment	1,251,452	1,240,674
Capital lease equipment	1,635,064	1,620,982
Fixtures	102,936	102,049
Vehicles	40,453	40,104
Total equipment	3,108,166	3,081,396
Less accumulated depreciation	1,359,129	1,329,569
Less impairment of the equipment	1,377,533	(1,365,669)
Property and equipment, net	$ 371,504	$ 386,158
Office Equipment
Estimated Useful Lives, minimum	5 years
Estimated Useful Lives, maximum	10 years
Medical equipment
Estimated Useful Lives	5 years
Capital Lease Equipment
Estimated Useful Lives	5 years
Fixtures
Estimated Useful Lives	10 years
Vehicles
Estimated Useful Lives	5 years

7. CAPITAL LEASE OBLIGATION (Details Narrative)	Mar. 31, 2017 USD ($)
Capital Lease Obligation Details Narrative
Capital lease payable under sales lease back	$ 100,000
Impairment loss to equipment under lease	1,377,533
Capital lease payable	$ 425,000

8. OTHER PAYABLES (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Other Payables Details
Advance from customers	$ 0	$ 555
Accrued Salary	53,590	53,128
Tax payable	699,864	694,039
Accrued Professional Expenses	434,139	387,160
Unemployment & Retirement Insurance Payable	33,475	27,133
Deposit Payable	31,401	31,131
Employees Training Fees Payable	16,275	16,135
Rent Deposit Payable	5,102	5,058
Other Payable	44,863	54,837
Total	$ 1,318,709	$ 1,269,176

9. STOCKHOLDERS' EQUITY (Details)	3 Months Ended
9. STOCKHOLDERS' EQUITY (Details)	Mar. 31, 2017 $ / shares
Notes to Financial Statements
Expected volatility	105.00%
Expected Dividends	0.00%
Stock price	$ 0.24
Expected term (in years)	3 years
Risk-free rate	1.32%

9. STOCKHOLDERS' EQUITY (Details 1)	3 Months Ended
9. STOCKHOLDERS' EQUITY (Details 1)	Mar. 31, 2017 USD ($) $ / shares shares
Number of Shares
Outstanding at beginning of period \| shares	100,000
Granted \| shares	0
Exercised \| shares	0
Cancelled/expired \| shares	0
Outstanding at end of the period \| shares	100,000
Exercisable \| shares	100,000
Weighted Average Exercise Price
Outstanding at beginning of period \| $ / shares	$ 0.24
Granted \| $ / shares	0.00
Exercised \| $ / shares	0.00
Cancelled/expired \| $ / shares	0.00
Outstanding at end of the period \| $ / shares	0.24
Exercisable \| $ / shares	$ .24
Aggregate Intrinsic Value
Outstanding at beginning of period \| $	$ 0
Granted \| $	0
Exercised \| $	0
Cancelled/expired \| $	0
Outstanding at end of the period \| $	0
Exercisable \| $	$ 0

9. STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	3 Months Ended
9. STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Stockholders Equity Details Narrative
Preferred stock authorized	20,000,000		20,000,000
Preferred stock par value	$ 0.001		$ .001
Preferred stock shares issued	0		0
Preferred stock shares outstanding	0		0
Common Stock shares Authorized	50,000,000		50,000,000
Common Stock par value	$ 0.001		$ .001
Accumulated deficits	$ 7,369,605		$ 7,206,416
Stock-based compensation costs	$ 0	$ 0

10. RELATED PARTY TRANSACTIONS AND COMMITMENTS (Details)	Mar. 31, 2017 USD ($)
2017	$ 39,226
2018	8,717
Total	47,943
Related Party [Member]
2017	39,226
2018	8,717
Total	$ 47,943